Inotrem

Inotrem is a French biotechnology company founded in 2013, focusing on immunomodulatory therapies that target the TREM-1 pathway to address life-threatening inflammatory syndromes. The company was established by a team of experts, including Dr. Jean-Jacques Garaud, Prof. Sébastien Gibot, and Dr. Marc Derive, with Sven Zimmermann as CEO. Inotrem's research is rooted in the discovery of TREM-1, which amplifies the immune response and can lead to excessive inflammation.

The company's lead drug candidate, INO-01 (Nangibotide), is a first-in-class anti-TREM-1 peptide that has shown safety and efficacy in Phase II clinical trials for conditions like septic shock and severe COVID-19. Inotrem is currently conducting the ASTONISH trial, a global Phase IIb study to further validate its clinical efficacy. Additionally, Inotrem has developed a companion diagnostic tool in collaboration with Roche Diagnostics, utilizing soluble TREM-1 as a biomarker to identify patients who may benefit from treatment. The company is also exploring therapeutic applications for myocardial infarction and chronic inflammatory diseases.